Clinical Trials · global
Vision improvement meets target, but safety gap emerges: remigromig reports diabetic eye disease trial results
A novel antibody that activates Wnt signaling met the noninferiority criterion against the comparator drug for one-year vision outcomes but did not demonstrate superior efficacy. A higher rate of adverse events related to proliferative retinopathy calls for a more detailed assessment of the benefits and risks of this new treatment approach.
For patients with diabetic macular edema, seeing more clearly is an important treatment goal, but improvements in vision may not reflect the full picture of retinal disease. On October 10, Merck presented one-year trial results for remigromig at the American Academy of Ophthalmology annual meeting: the investigational drug met the prespecified criterion for noninferiority in vision while showing more adverse events related to proliferative diabetic retinopathy. Together, these two findings are central to assessing its clinical value.
The phase 2b/3 trial, called BRUNELLO, enrolled 984 adults and used a randomized, double-blind design. Participants received 0.5 mg or 0.8 mg of remigromig, or 0.5 mg of ranibizumab; all received intravitreal injections every four weeks during the first year. Retinal Physician reported that approximately one-quarter of participants had previously received anti–vascular endothelial growth factor (VEGF) treatment, meaning the study population also included patients with prior treatment experience.
After one year, best-corrected visual acuity improved by an average of 9.1 and 8.7 eye-chart letters in the two remigromig dose groups, respectively, compared with 11.8 letters in the ranibizumab group. Both investigational drug groups met the prespecified noninferiority margin, meaning the differences fell within the range allowed in advance by the trial, rather than indicating identical effects. Neither of the two key secondary endpoints—vision improvement and change in central macular thickness—demonstrated that remigromig was superior to the comparator drug.
remigromig seeks to address edema through a different biological mechanism. Vascular damage caused by diabetes allows fluid to leak into the macula, which is responsible for fine-detail vision; this trispecific antibody activates Wnt signaling with the aim of supporting the repair and maintenance of the blood-retinal barrier. Its mechanism differs from ranibizumab’s inhibition of VEGF, and it is not designed to directly inhibit new blood vessel formation.
The safety differences were concentrated in events related to proliferative diabetic retinopathy. Rates were 6.7% and 6.1% in the 0.5 mg and 0.8 mg remigromig groups, respectively, compared with 0.9% in the ranibizumab group; this category includes new-onset proliferative disease and related events, so not all events can be interpreted as new cases. The proportions discontinuing treatment because of adverse events were 4.9%, 4.5%, and 0.9%, in the same order. By comparison, rates of intraocular inflammation were similar, at 1.8%, 1.5%, and 1.8%, respectively, and the study reported no retinal vasculitis.
Merck suggested that this difference may be related to remigromig’s lack of direct inhibition of new blood vessel formation and the possibility that the disease may continue to progress naturally, but the cause requires further analysis. Ophthalmology Times quoted trial presenter Donald J. D’Amico as saying that, among patients who reached an endpoint related to proliferative disease, 85% still had improved vision at one year. This shows that vision improvement and disease progression can occur at the same time; vision figures alone cannot resolve the questions raised by the higher event rates.
The results released so far cover one year and are not yet sufficient to determine the balance of long-term benefits and risks. In BRUNELLO’s second year, treatment intervals will be adjusted according to individual patient circumstances to examine whether efficacy can be maintained and whether there may be an opportunity to reduce the injection burden. D’Amico said that results from BAROLO, another trial with a similar design, are expected in the coming months. remigromig remains an investigational drug; subsequent data must further clarify which patients may benefit and how the higher rate of events related to proliferative disease affects its overall treatment value.